BTK inhibitors: safety + efficacy = outcome
- PMID: 37616021
- DOI: 10.1182/blood.2023020974
BTK inhibitors: safety + efficacy = outcome
Comment on
-
Detailed safety profile of acalabrutinib vs ibrutinib in previously treated chronic lymphocytic leukemia in the ELEVATE-RR trial.Blood. 2023 Aug 24;142(8):687-699. doi: 10.1182/blood.2022018818. Blood. 2023. PMID: 37390310 Free PMC article. Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources

